PF-06645849

PF-06645849 is a novel recombinant human fibroblast growth factor 21 (FGF21) analog engineered for enhanced pharmacokinetic and pharmacodynamic properties. It is designed as an Fc-fusion protein with specific amino acid substitutions (R19V, N171) to improve its stability and efficacy. The drug acts as an agonist of the FGF21 receptor complex, which includes FGFR1c and the co-receptor β-Klotho, leading to beneficial metabolic effects such as improved glucose homeostasis and reduced body weight in preclinical models. Developed by Pfizer, PF-06645849 has demonstrated greater body weight loss at lower and less frequent subcutaneous doses compared to earlier FGF21 analogs like PF-05231023. Its profile supports potential use as a weekly or twice-monthly subcutaneous therapy for chronic metabolic diseases including non-alcoholic steatohepatitis (NASH), obesity, and related disorders[1][3][4].